BioArctic to end SC-0806 development in complete spinal cord injury based on interim phase I/II data Nov. 19, 2019
A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495 Nov. 19, 2019
RSS